{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:33:30Z","timestamp":1787729610539,"version":"build-2784847793"},"reference-count":143,"publisher":"American Medical Association (AMA)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:sec id=\"ab-jus230003-1\"><jats:title>Importance<\/jats:title><jats:p>Latent tuberculosis infection (LTBI) can progress to active tuberculosis disease, causing morbidity and mortality.<\/jats:p><\/jats:sec><jats:sec id=\"ab-jus230003-2\"><jats:title>Objective<\/jats:title><jats:p>To review the evidence on benefits and harms of screening for and treatment of LTBI in adults to inform the US Preventive Services Task Force (USPSTF).<\/jats:p><\/jats:sec><jats:sec id=\"ab-jus230003-3\"><jats:title>Data Sources<\/jats:title><jats:p>PubMed\/MEDLINE, Cochrane Library, and trial registries through December 3, 2021; references; experts; literature surveillance through January 20, 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-jus230003-4\"><jats:title>Study Selection<\/jats:title><jats:p>English-language studies of LTBI screening, LTBI treatment, or accuracy of the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs). Studies of LTBI screening and treatment for public health surveillance or disease management were excluded.<\/jats:p><\/jats:sec><jats:sec id=\"ab-jus230003-5\"><jats:title>Data Extraction and Synthesis<\/jats:title><jats:p>Dual review of abstracts, full-text articles, and study quality; qualitative synthesis of findings; meta-analyses conducted when a sufficient number of similar studies were available.<\/jats:p><\/jats:sec><jats:sec id=\"ab-jus230003-6\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Screening test accuracy; development of active tuberculosis disease, transmission, quality of life, mortality, and harms.<\/jats:p><\/jats:sec><jats:sec id=\"ab-jus230003-7\"><jats:title>Results<\/jats:title><jats:p>A total of 113 publications were included (112 studies; N\u2009=\u200969\u202f009). No studies directly evaluated the benefits and harms of screening. Pooled estimates for sensitivity of the TST were 0.80 (95% CI, 0.74-0.87) at the 5-mm induration threshold, 0.81 (95% CI, 0.76-0.87) at the 10-mm threshold, and 0.60 (95% CI, 0.46-0.74) at the 15-mm threshold. Pooled estimates for sensitivity of IGRA tests ranged from 0.81 (95% CI, 0.79-0.84) to 0.90 (95% CI, 0.87-0.92). Pooled estimates for specificity of screening tests ranged from 0.95 to 0.99. For treatment of LTBI, a large (n\u2009=\u200927\u202f830), good-quality randomized clinical trial found a relative risk (RR) for progression to active tuberculosis at 5 years of 0.35 (95% CI, 0.24-0.52) for 24 weeks of isoniazid compared with placebo (number needed to treat, 112) and an increase in hepatotoxicity (RR, 4.59 [95% CI, 2.03-10.39]; number needed to harm, 279). A previously published meta-analysis reported that multiple regimens were efficacious compared with placebo or no treatment. Meta-analysis found greater risk for hepatotoxicity with isoniazid than with rifampin (pooled RR, 4.22 [95% CI, 2.21-8.06]; n\u2009=\u20097339).<\/jats:p><\/jats:sec><jats:sec id=\"ab-jus230003-8\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>No studies directly evaluated the benefits and harms of screening for LTBI compared with no screening. TST and IGRAs were moderately sensitive and highly specific. Treatment of LTBI with recommended regimens reduced the risk of progression to active tuberculosis. Isoniazid was associated with higher rates of hepatotoxicity than placebo or rifampin.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2023.3954","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T15:11:41Z","timestamp":1683040301000},"page":"1495","source":"Crossref","is-referenced-by-count":67,"title":["Screening for Latent Tuberculosis Infection in Adults"],"prefix":"10.1001","volume":"329","author":[{"given":"Daniel E.","family":"Jonas","sequence":"first","affiliation":[{"name":"RTI International\u2013University of North Carolina at Chapel Hill Evidence-based Practice Center, Research Triangle Park"},{"name":"Department of Internal Medicine, The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R.","family":"Riley","sequence":"additional","affiliation":[{"name":"RTI International\u2013University of North Carolina at Chapel Hill Evidence-based Practice Center, Research Triangle Park"},{"name":"Department of Internal Medicine, The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory P.","family":"Coffey","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The Ohio State University College of Medicine, Columbus"},{"name":"Global One Health Initiative, The Ohio State University, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary N.","family":"Asher","sequence":"additional","affiliation":[{"name":"RTI International\u2013University of North Carolina at Chapel Hill Evidence-based Practice Center, Research Triangle Park"},{"name":"Department of Family Medicine, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Berry","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of North Carolina at Chapel Hill"},{"name":"Department of Family Medicine and Community Health, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niketa","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of North Carolina at Chapel Hill"},{"name":"North Carolina Department of Health and Human Services, Division of Public Health, Raleigh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Balio","sequence":"additional","affiliation":[{"name":"RTI International\u2013University of North Carolina at Chapel Hill Evidence-based Practice Center, Research Triangle Park"},{"name":"Center for Rural Health Research, East Tennessee State University, Johnson City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane E.","family":"Voisin","sequence":"additional","affiliation":[{"name":"RTI International\u2013University of North Carolina at Chapel Hill Evidence-based Practice Center, Research Triangle Park"},{"name":"Department of Internal Medicine, The Ohio State University College of Medicine, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila C.","family":"Kahwati","sequence":"additional","affiliation":[{"name":"RTI International\u2013University of North Carolina at Chapel Hill Evidence-based Practice Center, Research Triangle Park"},{"name":"RTI International, Research Triangle Park, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"jus230003r1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling.","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"issue":"11","key":"jus230003r8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011-2012.","volume":"10","author":"Miramontes","year":"2015","journal-title":"PLoS One"},{"key":"jus230003r11","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"8","key":"jus230003r12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"issue":"3","key":"jus230003r14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"1","key":"jus230003r15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data.","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"jus230003r16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12874-016-0108-4","article-title":"Assessing variability in results in systematic reviews of diagnostic studies.","volume":"16","author":"Naaktgeboren","year":"2016","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"jus230003r17","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3348\/kjr.2015.16.6.1188","article-title":"Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers\u2014part ii: statistical methods of meta-analysis.","volume":"16","author":"Lee","year":"2015","journal-title":"Korean J Radiol"},{"issue":"12","key":"jus230003r18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082727","article-title":"Tuberculosis screening by tuberculosis skin test or QuantiFERON-TB Gold In-Tube assay among an immigrant population with a high prevalence of tuberculosis and BCG vaccination.","volume":"8","author":"Painter","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"jus230003r19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1164\/rccm.201107-1244OC","article-title":"Discordance among commercially available diagnostics for latent tuberculosis infection.","volume":"185","author":"Mancuso","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"jus230003r20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1086\/521107","article-title":"Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis.","volume":"45","author":"Mazurek","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"7","key":"jus230003r21","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1086\/521106","article-title":"Detection of Mycobacterium tuberculosis infection in United States Navy recruits using the tuberculin skin test or whole-blood interferon-gamma release assays.","volume":"45","author":"Mazurek","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"22","key":"jus230003r22","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1001\/jama.293.22.2756","article-title":"Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country.","volume":"293","author":"Kang","year":"2005","journal-title":"JAMA"},{"issue":"8","key":"jus230003r23","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1128\/JCM.02411-05","article-title":"Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis.","volume":"44","author":"Tsiouris","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"3","key":"jus230003r24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1309\/LTETF72AHG94KGUY","article-title":"Evaluation of an in vitro assay for interferon gamma production in response to the Mycobacterium tuberculosis\u2013synthesized peptide antigens ESAT-6 and CFP-10 and the PPD skin test.","volume":"125","author":"Taggart","year":"2006","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"jus230003r25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.diagmicrobio.2011.02.011","article-title":"Risk factors for false-negative results of QuantiFERON-TB Gold In-Tube assay in non-HIV-infected patients with culture-confirmed tuberculosis.","volume":"70","author":"Kim","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"jus230003r26","first-page":"310","article-title":"Tuberculin skin test: estimation of positive and negative predictive values from routine data.","volume":"9","author":"Berkel","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"jus230003r27","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1128\/CDLI.11.6.1089-1093.2004","article-title":"Evaluation of an in vitro assay for gamma interferon production in response to Mycobacterium tuberculosis infections.","volume":"11","author":"Taggart","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"6","key":"jus230003r28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0196-6553(02)48240-5","article-title":"Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection.","volume":"31","author":"Fietta","year":"2003","journal-title":"Am J Infect Control"},{"issue":"11","key":"jus230003r29","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1086\/cid.2002.34.issue-11","article-title":"Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations.","volume":"34","author":"Bellete","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"14","key":"jus230003r30","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1001\/jama.286.14.1740","article-title":"Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection.","volume":"286","author":"Mazurek","year":"2001","journal-title":"JAMA"},{"issue":"10","key":"jus230003r31","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.rmed.2010.05.011","article-title":"Limited usefulness of QuantiFERON-TB Gold In-Tube for monitoring anti-tuberculosis therapy.","volume":"104","author":"Bocchino","year":"2010","journal-title":"Respir Med"},{"issue":"4, pt 1","key":"jus230003r32","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1164\/ajrccm.161.4.9906050","article-title":"Comparison testing of current (PPD-S1) and proposed (PPD-S2) reference tuberculin standards.","volume":"161","author":"Villarino","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"jus230003r33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/jama.281.2.169","article-title":"Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection.","volume":"281","author":"Villarino","year":"1999","journal-title":"JAMA"},{"issue":"4","key":"jus230003r34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1378\/chest.99.4.883","article-title":"Tuberculous pleural effusion: twenty-year experience.","volume":"99","author":"Seibert","year":"1991","journal-title":"Chest"},{"issue":"5","key":"jus230003r35","first-page":"545","article-title":"Interferon-gamma release assay clarifies the effect of bacille Calmette-Gu\u00e9rin vaccination in Greek army recruits.","volume":"14","author":"Katsenos","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11-12","key":"jus230003r36","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3109\/00365540903214298","article-title":"Clinical utility of the QuantiFERON-TB Gold In-Tube test for the diagnosis of active pulmonary tuberculosis.","volume":"41","author":"Park","year":"2009","journal-title":"Scand J Infect Dis"},{"issue":"11","key":"jus230003r37","first-page":"1416","article-title":"Evaluation of an interferon-gamma release assay, T-SPOT.TB, in a population with a low prevalence of tuberculosis.","volume":"13","author":"Bienek","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"jus230003r38","first-page":"50","article-title":"Evaluation of cut-off values of interferon-gamma-based assays in the diagnosis of M. tuberculosis infection.","volume":"12","author":"Soysal","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"jus230003r39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.7883\/yoken.63.433","article-title":"Is the T-cell-based interferon-gamma releasing assay feasible for diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country?","volume":"63","author":"Dilektasli","year":"2010","journal-title":"Jpn J Infect Dis"},{"issue":"2","key":"jus230003r40","doi-asserted-by":"publisher","first-page":"149","DOI":"10.7883\/yoken.JJID.2009.149","article-title":"The evaluation of the Quantiferon-TB Gold test in pulmonary and extrapulmonary tuberculosis.","volume":"62","author":"Ak","year":"2009","journal-title":"Jpn J Infect Dis"},{"issue":"9","key":"jus230003r41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107208","article-title":"Interferon-gamma assay in combination with tuberculin skin test are insufficient for the diagnosis of culture-negative pulmonary tuberculosis.","volume":"9","author":"Wlodarczyk","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"jus230003r42","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1183\/13993003.01464-2015","article-title":"Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection.","volume":"47","author":"Hoff","year":"2016","journal-title":"Eur Respir J"},{"issue":"8","key":"jus230003r43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182998","article-title":"Assessment of the influence of direct tobacco smoke on infection and active TB management.","volume":"12","author":"Altet","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"jus230003r44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.5588\/ijtld.18.0137","article-title":"Interaction between C-Tb and PPD given concomitantly in a split-body randomised controlled trial.","volume":"23","author":"Aggerbeck","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"jus230003r45","doi-asserted-by":"publisher","first-page":"582","DOI":"10.5588\/ijtld.14.0553","article-title":"Reduced sensitivity of the QuantiFERON(\u00ae) test in diabetic patients with smear-negative tuberculosis.","volume":"19","author":"Choi","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"jus230003r46","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2019.181109","article-title":"Performance evaluation of IGRA-ELISA and T-SPOT.TB for diagnosing tuberculosis infection.","volume":"65","author":"Zhu","year":"2019","journal-title":"Clin Lab"},{"issue":"4","key":"jus230003r47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/00365548.2014.988749","article-title":"Development and evaluation of a new interferon-gamma release assay for the diagnosis of tuberculosis infection in HIV-infected individuals in China.","volume":"47","author":"Yu","year":"2015","journal-title":"Infect Dis (Lond)"},{"issue":"2","key":"jus230003r48","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3904\/kjim.2016.199","article-title":"Qualitative and quantitative results of interferon-? release assays for monitoring the response to anti-tuberculosis treatment.","volume":"32","author":"Park","year":"2017","journal-title":"Korean J Intern Med"},{"issue":"8","key":"jus230003r49","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ebiom.2015.05.026","article-title":"A Mycobacterium tuberculosis dormancy antigen differentiates latently infected bacillus Calmette-Gu\u00e9rin\u2013vaccinated individuals.","volume":"2","author":"Pe\u00f1a","year":"2015","journal-title":"EBioMedicine"},{"issue":"2","key":"jus230003r50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.diagmicrobio.2011.05.013","article-title":"Diagnostic performance of whole-blood interferon-? assay and enzyme-linked immunospot assay for active tuberculosis\u2019.","volume":"71","author":"Lai","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"jus230003r51","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1183\/09031936.00067307","article-title":"Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy.","volume":"30","author":"Losi","year":"2007","journal-title":"Eur Respir J"},{"issue":"6","key":"jus230003r52","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1469-0691.2006.01391.x","article-title":"Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study.","volume":"12","author":"Goletti","year":"2006","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"jus230003r53","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1183\/09031936.00028507","article-title":"Quantitative scoring of an interferon-gamma assay for differentiating active from latent tuberculosis.","volume":"30","author":"Janssens","year":"2007","journal-title":"Eur Respir J"},{"issue":"6","key":"jus230003r54","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1128\/JCM.02403-07","article-title":"Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis.","volume":"46","author":"Chee","year":"2008","journal-title":"J Clin Microbiol"},{"issue":"5","key":"jus230003r55","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jinf.2011.06.010","article-title":"Diagnostic performance of T-SPOT.TB for extrapulmonary tuberculosis according to the site of infection.","volume":"63","author":"Cho","year":"2011","journal-title":"J Infect"},{"issue":"6","key":"jus230003r56","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jinf.2011.04.003","article-title":"Limited added value of T-SPOT.TB blood test in diagnosing active TB: a prospective Bayesian analysis.","volume":"62","author":"Boyd","year":"2011","journal-title":"J Infect"},{"issue":"1","key":"jus230003r57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.diagmicrobio.2010.11.012","article-title":"Diagnostic value of an enzyme-linked immunospot assay for interferon-? in cutaneous tuberculosis.","volume":"70","author":"Lai","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"jus230003r58","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.tube.2011.01.001","article-title":"A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis.","volume":"91","author":"Ruhwald","year":"2011","journal-title":"Tuberculosis (Edinb)"},{"issue":"2","key":"jus230003r59","first-page":"179","article-title":"The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes.","volume":"15","author":"Walsh","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"jus230003r60","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3109\/00365548.2010.490237","article-title":"Enzyme-linked immunospot assay for interferon-gamma to support the diagnosis of tuberculosis in diabetic patients.","volume":"42","author":"Tan","year":"2010","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"jus230003r61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00430-008-0102-5","article-title":"Comparison of performance in two diagnostic methods for tuberculosis infection.","volume":"198","author":"Higuchi","year":"2009","journal-title":"Med Microbiol Immunol"},{"issue":"8","key":"jus230003r62","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/00365540801932454","article-title":"Clinical evaluation for diagnosing active TB disease and transitional change of two commercial blood tests.","volume":"40","author":"Kobashi","year":"2008","journal-title":"Scand J Infect Dis"},{"issue":"10","key":"jus230003r63","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2169\/internalmedicine.51.5703","article-title":"Usefulness of tuberculin skin test and three interferon-gamma release assays for the differential diagnosis of pulmonary tuberculosis.","volume":"51","author":"Kobashi","year":"2012","journal-title":"Intern Med"},{"issue":"3","key":"jus230003r64","doi-asserted-by":"publisher","first-page":"268","DOI":"10.4103\/0366-6999.223860","article-title":"Interferon-gamma release assay is not appropriate for the diagnosis of active tuberculosis in high-burden tuberculosis settings: a retrospective multicenter investigation.","volume":"131","author":"Kang","year":"2018","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"jus230003r65","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1038\/s41598-018-24285-3","article-title":"Prospective comparison of QFT-GIT and T-SPOT.TB assays for diagnosis of active tuberculosis.","volume":"8","author":"Du","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"jus230003r66","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.2018.32.issue-2","article-title":"The risk factor of false-negative and false-positive for T-SPOT.TB in active tuberculosis.","volume":"32","author":"Di","year":"2018","journal-title":"J Clin Lab Anal"},{"issue":"6","key":"jus230003r67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156917","article-title":"Comparison of the sensitivity of QuantiFERON-TB Gold In-Tube and T-SPOT.TB according to patient age.","volume":"11","author":"Bae","year":"2016","journal-title":"PLoS One"},{"issue":"23","key":"jus230003r68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta23230","article-title":"Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation.","volume":"23","author":"Takwoingi","year":"2019","journal-title":"Health Technol Assess"},{"issue":"7","key":"jus230003r69","doi-asserted-by":"publisher","first-page":"811","DOI":"10.4103\/0366-6999.202738","article-title":"Diagnostic significance of Mycobacterium tuberculosis T-cell assays for active tuberculosis.","volume":"130","author":"Xuan","year":"2017","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"jus230003r70","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jiac.2020.06.019","article-title":"Comparison of QuantiFERON-TB Gold Plus, QuantiFERON-TB Gold In-Tube, and T-SPOT.TB among patients with tuberculosis.","volume":"26","author":"Takeda","year":"2020","journal-title":"J Infect Chemother"},{"issue":"3","key":"jus230003r71","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jiac.2017.10.009","article-title":"Sensitivity and specificity of QuantiFERON-TB Gold Plus compared with QuantiFERON-TB Gold In-Tube and T-SPOT.TB on active tuberculosis in Japan.","volume":"24","author":"Takasaki","year":"2018","journal-title":"J Infect Chemother"},{"issue":"1","key":"jus230003r72","doi-asserted-by":"publisher","first-page":"7764","DOI":"10.1038\/s41598-017-07785-6","article-title":"Analysis of factors influencing diagnostic accuracy of T-SPOT.","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"jus230003r73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2018.01.007","article-title":"Evaluation of Mycobacterium tuberculosis\u2013specific antibody responses for the discrimination of active and latent tuberculosis infection.","volume":"70","author":"Wang","year":"2018","journal-title":"Int J Infect Dis"},{"issue":"4","key":"jus230003r74","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jinf.2014.12.018","article-title":"Risk factors for false-negative T-SPOT.TB assay results in patients with pulmonary and extra-pulmonary TB.","volume":"70","author":"Pan","year":"2015","journal-title":"J Infect"},{"issue":"12","key":"jus230003r75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166501","article-title":"Potential role for Mycobacterium tuberculosis specific IL-2 and IFN-? responses in discriminating between latent infection and active disease after long-term stimulation.","volume":"11","author":"Sun","year":"2016","journal-title":"PLoS One"},{"key":"jus230003r76","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijid.2015.09.004","article-title":"Multicenter clinical evaluation of three commercial reagent kits based on the interferon-gamma release assay for the rapid diagnosis of tuberculosis in China.","volume":"40","author":"Qiu","year":"2015","journal-title":"Int J Infect Dis"},{"issue":"4","key":"jus230003r77","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jinf.2018.04.011","article-title":"Combined IFN-? and TNF-a release assay for differentiating active tuberculosis from latent tuberculosis infection.","volume":"77","author":"Kim","year":"2018","journal-title":"J Infect"},{"issue":"4","key":"jus230003r78","doi-asserted-by":"publisher","first-page":"773","DOI":"10.7754\/Clin.Lab.2016.161007","article-title":"Factors contributing to false-negative enzyme-linked immunospot assay for interferon-gamma results in active tuberculosis.","volume":"63","author":"Lian","year":"2017","journal-title":"Clin Lab"},{"issue":"2","key":"jus230003r79","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1473-3099(18)30613-3","article-title":"Clinical utility of existing and second-generation interferon-? release assays for diagnostic evaluation of tuberculosis: an observational cohort study.","volume":"19","author":"Whitworth","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"jus230003r80","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/j.jiac.2021.08.016","article-title":"Clinical evaluation of QuantiFERON\u00ae-TB Gold Plus directly compared with QuantiFERON\u00ae-TB Gold In-Tube and T-Spot\u00ae.TB for active pulmonary tuberculosis in the elderly.","volume":"27","author":"Fukushima","year":"2021","journal-title":"J Infect Chemother"},{"issue":"11","key":"jus230003r81","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.3855\/jidc.12063","article-title":"Risk factors for negative T-SPOT.TB assay results in patients with confirmed active tuberculosis: a retrospective study.","volume":"14","author":"Shangguan","year":"2020","journal-title":"J Infect Dev Ctries"},{"issue":"6","key":"jus230003r82","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5588\/ijtld.17.0721","article-title":"Multicenter study of QuantiFERON\u00ae-TB Gold Plus in patients with active tuberculosis.","volume":"22","author":"Horne","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"jus230003r83","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.cmi.2016.05.006","article-title":"Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT.","volume":"22","author":"Hoffmann","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"jus230003r84","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jiac.2020.11.023","article-title":"IL-1RA in the supernatant of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus is useful for discriminating active tuberculosis from latent infection.","volume":"27","author":"Akashi","year":"2021","journal-title":"J Infect Chemother"},{"issue":"4","key":"jus230003r85","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jinf.2019.01.007","article-title":"CD8 response measured by QuantiFERON-TB Gold Plus and tuberculosis disease status.","volume":"78","author":"Lee","year":"2019","journal-title":"J Infect"},{"key":"jus230003r86","doi-asserted-by":"publisher","first-page":"30617","DOI":"10.1038\/srep30617","article-title":"Evaluation of QuantiFERON-TB gold plus for detection of Mycobacterium tuberculosis infection in Japan.","volume":"6","author":"Yi","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"jus230003r87","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00629-18","article-title":"Specificity of QuantiFERON-TB Plus, a new-generation interferon gamma release assay.","volume":"56","author":"Siegel","year":"2018","journal-title":"J Clin Microbiol"},{"issue":"3","key":"jus230003r88","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jinf.2019.07.007","article-title":"Prospective evaluation of host biomarkers other than interferon gamma in QuantiFERON Plus supernatants as candidates for the diagnosis of tuberculosis in symptomatic individuals.","volume":"79","author":"Manngo","year":"2019","journal-title":"J Infect"},{"issue":"12","key":"jus230003r89","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.jiac.2021.08.003","article-title":"Comparison of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube tests for patients with active and latent tuberculosis: a prospective cohort study.","volume":"27","author":"Lee","year":"2021","journal-title":"J Infect Chemother"},{"issue":"7","key":"jus230003r90","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/jcm10071376","article-title":"Is the new interferon-gamma releasing assay beneficial for the diagnosis of latent and active Mycobacterium tuberculosis infections in tertiary care setting?","volume":"10","author":"Jung","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"jus230003r91","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4103\/0377-4929.118694","article-title":"Evaluation of a new tuberculosis-related interferon gamma release assay for tuberculosis infection diagnosis in Huzhou, eastern China.","volume":"56","author":"Qian","year":"2013","journal-title":"Indian J Pathol Microbiol"},{"issue":"1","key":"jus230003r92","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.diagmicrobio.2013.05.020","article-title":"Characteristics of IFN-? responses in IGRA among pulmonary TB suspects in a TB-endemic area.","volume":"77","author":"Feng","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"9","key":"jus230003r93","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1128\/CVI.00290-13","article-title":"Effect of prolonged incubation time on results of the QuantiFERON TB gold in-tube assay for diagnosis of latent tuberculosis infection.","volume":"20","author":"Min","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"jus230003r94","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jinf.2013.06.005","article-title":"Factors influencing discordant results of the QuantiFERON-TB Gold In-tube test in patients with active TB.","volume":"67","author":"Jeon","year":"2013","journal-title":"J Infect"},{"issue":"1","key":"jus230003r95","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1128\/CVI.00481-12","article-title":"Mycobacterium tuberculosis region of difference (RD) 2 antigen Rv1985c and RD11 antigen Rv3425 have the promising potential to distinguish patients with active tuberculosis from M. bovis BCG-vaccinated individuals.","volume":"20","author":"Wang","year":"2013","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"jus230003r96","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.diagmicrobio.2012.09.015","article-title":"Interferon gamma mRNA quantitative real-time polymerase chain reaction for the diagnosis of latent tuberculosis: a novel interferon gamma release assay.","volume":"75","author":"Kim","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"jus230003r97","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jinf.2012.08.020","article-title":"Comparison of whole-blood interferon-? assay and flow cytometry for the detection of tuberculosis infection.","volume":"66","author":"Lee","year":"2013","journal-title":"J Infect"},{"issue":"2","key":"jus230003r98","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s15010-007-6114-z","article-title":"Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment.","volume":"35","author":"Pai","year":"2007","journal-title":"Infection"},{"issue":"5","key":"jus230003r99","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jinf.2008.02.011","article-title":"Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection.","volume":"56","author":"Harada","year":"2008","journal-title":"J Infect"},{"key":"jus230003r100","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/1471-2334-10-354","article-title":"Performance of QuantiFERON-TB Gold In-Tube (QFTGIT) for the diagnosis of Mycobacterium tuberculosis (Mtb) infection in Afar Pastoralists, Ethiopia.","volume":"10","author":"Legesse","year":"2010","journal-title":"BMC Infect Dis"},{"key":"jus230003r101","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2334-7-122","article-title":"Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia.","volume":"7","author":"Adetifa","year":"2007","journal-title":"BMC Infect Dis"},{"issue":"1","key":"jus230003r102","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3855\/jidc.2098","article-title":"Utility of an interferon-gamma release assay as a potential diagnostic aid for active pulmonary tuberculosis.","volume":"6","author":"Taki-Eddin","year":"2012","journal-title":"J Infect Dev Ctries"},{"issue":"10","key":"jus230003r103","doi-asserted-by":"publisher","first-page":"O600","DOI":"10.1111\/1469-0691.12478","article-title":"The microbiological diagnosis of tuberculous meningitis: results of Haydarpasa-1 study.","volume":"20","author":"Erdem","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"jus230003r104","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1093\/cid\/ciu045","article-title":"Diagnostic performance of the QuantiFERON-TB Gold In-Tube assay and factors associated with nonpositive results in patients with miliary tuberculosis.","volume":"58","author":"Kim","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jus230003r106","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13104-018-3410-x","article-title":"QuantiFERON-TB Gold In-Tube test for the diagnosis of active and latent tuberculosis in selected health facilities of Addis Ababa, Ethiopia.","volume":"11","author":"Niguse","year":"2018","journal-title":"BMC Res Notes"},{"issue":"10","key":"jus230003r107","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01048-19","article-title":"QuantiFERON-TB performs better in children, including infants, than in adults with active tuberculosis: a multicenter study.","volume":"57","author":"Lombardi","year":"2019","journal-title":"J Clin Microbiol"},{"issue":"3","key":"jus230003r108","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/labmed\/lmx022","article-title":"Diagnostic utility of new equation for active tuberculosis based on parameters of interferon-? release assay.","volume":"48","author":"Jeon","year":"2017","journal-title":"Lab Med"},{"issue":"12","key":"jus230003r109","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.5588\/ijtld.16.0223","article-title":"IFN-? promoter polymorphisms do not affect QuantiFERON TB Gold In-Tube test results in a Canadian population.","volume":"20","author":"Kiazyk","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"jus230003r110","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.tube.2015.05.001","article-title":"Cytokine and chemokine expression profiles in response to Mycobacterium tuberculosis stimulation are altered in HIV-infected compared to HIV-uninfected subjects with active tuberculosis.","volume":"95","author":"Waruk","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"issue":"6","key":"jus230003r111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129792","article-title":"Factors that predict negative results of QuantiFERON-TB Gold In-Tube test in patients with culture-confirmed tuberculosis: a multicenter retrospective cohort study.","volume":"10","author":"Kwon","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"jus230003r112","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.cyto.2015.07.028","article-title":"Evaluation of cytokine and chemokine response elicited by Rv2204c and Rv0753c to detect latent tuberculosis infection.","volume":"76","author":"Pathakumari","year":"2015","journal-title":"Cytokine"},{"key":"jus230003r113","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.rmed.2019.10.004","article-title":"Prognostic value of the mitogen response in the interferon-? release assay in patients with culture-confirmed tuberculosis.","volume":"158","author":"Huang","year":"2019","journal-title":"Respir Med"},{"issue":"9","key":"jus230003r114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043790","article-title":"Within-subject interlaboratory variability of QuantiFERON-TB Gold In-Tube tests.","volume":"7","author":"Whitworth","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"jus230003r115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086721","article-title":"Variability of the QuantiFERON-TB Gold In-Tube test using automated and manual methods.","volume":"9","author":"Whitworth","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"jus230003r116","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1164\/rccm.201302-0365OC","article-title":"Interferon-? release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States.","volume":"189","author":"Dorman","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"jus230003r117","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1128\/CVI.00456-08","article-title":"Variation in T-SPOT.TB spot interpretation between independent observers from different laboratories.","volume":"16","author":"Franken","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"5","key":"jus230003r118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097366","article-title":"Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants.","volume":"9","author":"O\u2019Shea","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"jus230003r119","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial.","volume":"60","author":"Thompson","year":"1982","journal-title":"Bull World Health Organ"},{"issue":"10","key":"jus230003r120","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"issue":"5","key":"jus230003r121","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults.","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"jus230003r122","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection.","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"jus230003r123","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.tube.2018.05.013","article-title":"Twelve-dose weekly rifapentine plus isoniazid for latent tuberculosis infection: a multicentre randomised controlled trial in Taiwan.","volume":"111","author":"Sun","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"issue":"4","key":"jus230003r124","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis.","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"jus230003r125","first-page":"732","article-title":"Isoniazid prophylaxis in contacts of persons with known tuberculosis: second report.","volume":"92","author":"Bush","year":"1965","journal-title":"Am Rev Respir Dis"},{"issue":"1","key":"jus230003r126","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1378\/chest.73.1.44","article-title":"Prophylaxis with isoniazid in inactive tuberculosis: a Veterans Administration Cooperative Study XII.","volume":"73","author":"Falk","year":"1978","journal-title":"Chest"},{"key":"jus230003r127","first-page":"161","article-title":"A controlled trial of isoniazid prophylaxis in mental institutions.","volume":"88","author":"Ferebee","year":"1963","journal-title":"Am Rev Respir Dis"},{"key":"jus230003r128","first-page":"169","article-title":"Long term isoniazid prophylaxis: controlled trial on INH prophylaxis after recent tuberculin conversion in young adults.","volume":"41","author":"Veening","year":"1968","journal-title":"Bull Int Union Tuberc"},{"issue":"3","key":"jus230003r129","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(19)30575-4","article-title":"Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.","volume":"20","author":"Campbell","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"jus230003r130","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"jus230003r131","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1078345811435973","article-title":"Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence.","volume":"18","author":"White","year":"2012","journal-title":"J Correct Health Care"},{"issue":"4","key":"jus230003r132","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis study.","volume":"61","author":"Sterling","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"jus230003r133","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12879-021-05766-9","article-title":"An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.","volume":"21","author":"Surey","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"6","key":"jus230003r134","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01470-2018","article-title":"Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study.","volume":"52","author":"Gao","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"jus230003r135","first-page":"219","article-title":"Isoniazid (INH) prophylaxis in inactive pulmonary tuberculosis: report of a Veterans Administration Cooperative Study.","volume":"51","author":"Falk","year":"1976","journal-title":"Bull Int Union Tuberc"},{"issue":"2","key":"jus230003r136","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-81-2-200","article-title":"The effect of isoniazid on transaminase levels.","volume":"81","author":"Bailey","year":"1974","journal-title":"Ann Intern Med"},{"issue":"9","key":"jus230003r137","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/archinte.1977.03630210016007","article-title":"Isoniazid chemoprophylaxis: association with detection and incidence of liver toxicity.","volume":"137","author":"Byrd","year":"1977","journal-title":"Arch Intern Med"},{"issue":"1","key":"jus230003r138","first-page":"193","article-title":"The IUAT trial on isoniazid preventive treatment in persons with fibrotic lung lesions.","volume":"51","author":"Krebs","year":"1976","journal-title":"Bull Int Union Tuberc"},{"issue":"9","key":"jus230003r139","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jama.2016.10357","article-title":"Primary care screening and treatment for latent tuberculosis infection in adults: evidence report and systematic review for the US Preventive Services Task Force.","volume":"316","author":"Kahwati","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"jus230003r140","doi-asserted-by":"publisher","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research.","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"issue":"3","key":"jus230003r141","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","article-title":"Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update.","volume":"149","author":"Pai","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"jus230003r142","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1378\/chest.09-2350","article-title":"Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis.","volume":"137","author":"Diel","year":"2010","journal-title":"Chest"},{"issue":"1","key":"jus230003r143","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1183\/09031936.00115110","article-title":"Interferon-? release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis.","volume":"37","author":"Diel","year":"2011","journal-title":"Eur Respir J"},{"key":"jus230003r2","volume-title":"Global Tuberculosis Report 2020","year":"2020"},{"key":"jus230003r10","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.3954","volume-title":"Screening for Latent Tuberculosis Infection in Adults: An Evidence Review for the US Preventive Services Task Force. Evidence Synthesis No. 226","author":"Jonas","year":"2023"},{"key":"jus230003r13","volume-title":"Comparative Effectiveness Review Methods: Clinical Heterogeneity","author":"West","year":"2010"},{"key":"jus230003r105","volume-title":"Assessment of the QuantiFERON-TB Gold In-Tube test for the Detection of Mycobacterium tuberculosis Infection in US Navy Recruits","author":"Lempp","year":"2015"},{"key":"jus230003r3","unstructured":"National Center for Health Statistics. Infectious disease. Centers for Disease Control and Prevention. Published 2020. Accessed October 29, 2020. https:\/\/www.cdc.gov\/nchs\/fastats\/infectious-disease.htm"},{"key":"jus230003r4","unstructured":"Tuberculosis: trends in tuberculosis, 2019. Centers for Disease Control and Prevention. Published 2019. Accessed November 8, 2020. https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/statistics\/tbtrends.htm"},{"key":"jus230003r5","unstructured":"Table 5: tuberculosis cases, percentages, and incidence rates per 100,000 population by origin of birth: United States, 1993-2020. Centers for Disease Control and Prevention. Published 2020. Accessed January 5, 2022. https:\/\/www.cdc.gov\/tb\/statistics\/reports\/2020\/table23.htm"},{"key":"jus230003r6","unstructured":"Tuberculosis (TB) (Mycobacterium tuberculosis). Centers for Disease Control and Prevention. Published 2015. Accessed June 8, 2015. https:\/\/ndc.services.cdc.gov\/case-definitions\/tuberculosis-2009\/"},{"key":"jus230003r7","unstructured":"Guidelines on the management of latent tuberculosis infection. World Health Organization. Published 2015. Accessed April 8, 2023. https:\/\/www.who.int\/publications\/i\/item\/9789241548908"},{"key":"jus230003r9","unstructured":"US Preventive Services Task Force Procedure Manual. US Preventive Services Task Force. Updated August 2022. Accessed February 16, 2023. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/procedure-manual"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2804320\/jama_jonas_2023_us_230003_1682611574.96436.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T22:19:58Z","timestamp":1702333198000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2804320"}},"subtitle":["Updated Evidence Report and Systematic Review for the US Preventive Services Task Force"],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":143,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,5,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.3954","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,2]]}}}